Cargando…
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392190/ https://www.ncbi.nlm.nih.gov/pubmed/32783920 http://dx.doi.org/10.1016/j.immuni.2020.07.020 |
_version_ | 1783564797358374912 |
---|---|
author | Atyeo, Caroline Fischinger, Stephanie Zohar, Tomer Slein, Matthew D. Burke, John Loos, Carolin McCulloch, Denise J. Newman, Kira L. Wolf, Caitlin Yu, Jingyou Shuey, Kiel Feldman, Jared Hauser, Blake Marie Caradonna, Tim Schmidt, Aaron G. Suscovich, Todd J. Linde, Caitlyn Cai, Yongfei Barouch, Dan Ryan, Edward T. Charles, Richelle C. Lauffenburger, Douglas Chu, Helen Alter, Galit |
author_facet | Atyeo, Caroline Fischinger, Stephanie Zohar, Tomer Slein, Matthew D. Burke, John Loos, Carolin McCulloch, Denise J. Newman, Kira L. Wolf, Caitlin Yu, Jingyou Shuey, Kiel Feldman, Jared Hauser, Blake Marie Caradonna, Tim Schmidt, Aaron G. Suscovich, Todd J. Linde, Caitlyn Cai, Yongfei Barouch, Dan Ryan, Edward T. Charles, Richelle C. Lauffenburger, Douglas Chu, Helen Alter, Galit |
author_sort | Atyeo, Caroline |
collection | PubMed |
description | As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development. |
format | Online Article Text |
id | pubmed-7392190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cell Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-73921902020-07-31 Distinct Early Serological Signatures Track with SARS-CoV-2 Survival Atyeo, Caroline Fischinger, Stephanie Zohar, Tomer Slein, Matthew D. Burke, John Loos, Carolin McCulloch, Denise J. Newman, Kira L. Wolf, Caitlin Yu, Jingyou Shuey, Kiel Feldman, Jared Hauser, Blake Marie Caradonna, Tim Schmidt, Aaron G. Suscovich, Todd J. Linde, Caitlyn Cai, Yongfei Barouch, Dan Ryan, Edward T. Charles, Richelle C. Lauffenburger, Douglas Chu, Helen Alter, Galit Immunity Report As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development. Cell Press 2020-09-15 /pmc/articles/PMC7392190/ /pubmed/32783920 http://dx.doi.org/10.1016/j.immuni.2020.07.020 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Report Atyeo, Caroline Fischinger, Stephanie Zohar, Tomer Slein, Matthew D. Burke, John Loos, Carolin McCulloch, Denise J. Newman, Kira L. Wolf, Caitlin Yu, Jingyou Shuey, Kiel Feldman, Jared Hauser, Blake Marie Caradonna, Tim Schmidt, Aaron G. Suscovich, Todd J. Linde, Caitlyn Cai, Yongfei Barouch, Dan Ryan, Edward T. Charles, Richelle C. Lauffenburger, Douglas Chu, Helen Alter, Galit Distinct Early Serological Signatures Track with SARS-CoV-2 Survival |
title | Distinct Early Serological Signatures Track with SARS-CoV-2 Survival |
title_full | Distinct Early Serological Signatures Track with SARS-CoV-2 Survival |
title_fullStr | Distinct Early Serological Signatures Track with SARS-CoV-2 Survival |
title_full_unstemmed | Distinct Early Serological Signatures Track with SARS-CoV-2 Survival |
title_short | Distinct Early Serological Signatures Track with SARS-CoV-2 Survival |
title_sort | distinct early serological signatures track with sars-cov-2 survival |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392190/ https://www.ncbi.nlm.nih.gov/pubmed/32783920 http://dx.doi.org/10.1016/j.immuni.2020.07.020 |
work_keys_str_mv | AT atyeocaroline distinctearlyserologicalsignaturestrackwithsarscov2survival AT fischingerstephanie distinctearlyserologicalsignaturestrackwithsarscov2survival AT zohartomer distinctearlyserologicalsignaturestrackwithsarscov2survival AT sleinmatthewd distinctearlyserologicalsignaturestrackwithsarscov2survival AT burkejohn distinctearlyserologicalsignaturestrackwithsarscov2survival AT looscarolin distinctearlyserologicalsignaturestrackwithsarscov2survival AT mccullochdenisej distinctearlyserologicalsignaturestrackwithsarscov2survival AT newmankiral distinctearlyserologicalsignaturestrackwithsarscov2survival AT wolfcaitlin distinctearlyserologicalsignaturestrackwithsarscov2survival AT yujingyou distinctearlyserologicalsignaturestrackwithsarscov2survival AT shueykiel distinctearlyserologicalsignaturestrackwithsarscov2survival AT feldmanjared distinctearlyserologicalsignaturestrackwithsarscov2survival AT hauserblakemarie distinctearlyserologicalsignaturestrackwithsarscov2survival AT caradonnatim distinctearlyserologicalsignaturestrackwithsarscov2survival AT schmidtaarong distinctearlyserologicalsignaturestrackwithsarscov2survival AT suscovichtoddj distinctearlyserologicalsignaturestrackwithsarscov2survival AT lindecaitlyn distinctearlyserologicalsignaturestrackwithsarscov2survival AT caiyongfei distinctearlyserologicalsignaturestrackwithsarscov2survival AT barouchdan distinctearlyserologicalsignaturestrackwithsarscov2survival AT ryanedwardt distinctearlyserologicalsignaturestrackwithsarscov2survival AT charlesrichellec distinctearlyserologicalsignaturestrackwithsarscov2survival AT lauffenburgerdouglas distinctearlyserologicalsignaturestrackwithsarscov2survival AT chuhelen distinctearlyserologicalsignaturestrackwithsarscov2survival AT altergalit distinctearlyserologicalsignaturestrackwithsarscov2survival |